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Identity 
Other names: DAB-2; DOC-2; DOC2; FLJ26626 
HGNC (Hugo): DAB2 
Location: 5p13.1 
Local order: The complement factor 9 (C9) gene is 
located at the 3'-end of the DAB2 gene. 
Note 
DAB2 was first identified as DOC-2, for differentially 
expressed in ovarian carcinoma, and subsequently as a 
protein whose phosphorylation is stimulated by CSF-1. 
DNA/RNA 
Description 
The DAB2 gene consists of 15 exons and 14 introns 
spanning in a region of 35 kb in size. 
Transcription 
The putative DAB2 promoter was identified within a 
420-bp sequence upstream of the exon1/intron1 
junction. DAB2 is alternatively spliced to generate 
several transcripts and proteins. The transcript has been 
detected in spleen, thymus, prostate, testis, small 
intestine, and abundant in ovary. 
Protein 
Note 
DAB2 plays a pivotal role in the control of cellular 
homeostasis. The adaptor protein DAB2 is implicated 
in several receptor-mediated signaling pathways, 
endocytosis, cell adhesive function, hematopoietic cell 
differentiation, and angiogenesis. 
 
Schematic representation of DAB2 domains. DAB2 possess a 
highly conserved N-terminal phosphotyrosine-
interacting/phosphotyrosine binding domain (PID/PTB), 
renamed the DAB homology domain, and a C-terminal proline-
rich domain (PRD). 
Description 
770 amino acids, molecular weight 82.5 kDa. DAB2 
contains an N-terminal PID/PTB domain (amino acid 
42-180) and three C-terminal proline-rich domains 
(amino acid 619-627, 663-671, and 714-722). A 
potential actin-binding motif, KKEK is present in the 
N-terminal domain. 
Expression 
Widely expressed. Cytoplasmic. DAB2 is expres-sed in 
many epithelial cell types and was suggested to have a 
role in epithelial organization. dab2 knock-out mice are 
embryonic lethal for defective visceral endoderm cell
organization. In fact, in dab2 (-/-) mice, the epithelial 
cells of the early embryos (visceral endoderm) mix 
within the interior rather then align as a layer covering 
the inner cell mass. The role of Dab2 in mediating 
directional trafficking of endocytic proteins to establish 
apical polarity is suggested as a mechanism for surface 
positioning of endoderm cells. 
Function 
The PID/PTB and PRD domains of DAB2 associate 
with several proteins, and these interactions have been 
shown to modulate protein trafficking,  
cytoskeleton organization, cell adhesion and migra-
tion, and cell signaling of various receptor protein-
tyrosine kinases. 
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Cell cycle: DAB2 was identified as a protein 
phosphorylated in response to mitogenic stimula-tion 
by CSF-1. In cells, protein phosphorylation of DAB2 
modulates its functional activity. Protein kinase C 
(PKC) and Cdc2 are the two known DAB2 kinases. 
The major PKC phosphorylation site has been mapped 
to Ser24 and it is essential for the inhibitory function of 
DAB2 in TPA-induced AP-1 gene transcription. DAB2 
is differentially phosphorylated during the cell cycle by 
cdc2, and its phosphorylation promotes the associati n 
of DAB2 with Pin1, that regulates the rate of DAB2 
dephosphorylation. 
Vesicle traffic: DAB2 plays a role in linking specific 
extracellular receptors to the endocytic machinery. 
DAB2 associates with AP-2-positive clathrin-coated 
structures, together with endocy-tosed trans-membrane 
proteins such as low-density lipoprotein (LDL) 
receptors and integrins. DAB2 also binds to the actin-
based myosin VI, mediating the attachment of cargos to 
motor proteins and regulating protein trafficking. 
Signaling pathways: 
- TGFbeta - Dab2 associates with Smad2 and Smad3, 
by a direct interaction with the PID/PTB domain of 
Dab2, and with TGFbeta receptor I and TGFbeta 
receptor II. Thus Dab2 may be an essential component 
of the TGFbeta signaling pathway allowing the 
transmission of signals from the TGFbeta receptors t  
the Smad family of transcriptional activators. 
- WNT - Dab2 associates with Axin and stabilizes its 
expression by preventing Axin interaction with the 
LRP5 co-receptor. Thus the interaction of Axin with 
beta-catenin results stabilized with an increase in beta-
catenin degradation and attenuation of Wnt signaling. 
- RAS/RAF/MAPK - In cell culture experiments, a 
Dab2 over-expression leads to suppression of c-Fos 
expression and cell growth inhibition without affecting 
MAPK activity. In vivo studies confirmed a Dab2 role 
in regulating c-Fos expression. A possible molecular 
mechanism of action is that Dab2 limits the entry of the 
activated MAPK into the nucleus. DAB2 can also 
interact with Grb2 through its PRD. Receptor tyrosine 
kinase activation by growth factors increases the 
binding of DAB2 to Grb2, which interrupts the bindig 
of SOS to Grb2 and leads to suppression of ERK 
activation. 
Cell adhesion: DAB2 is an adhesion-responsive 
phosphoprotein and plays a role in cell adhesion and 
spreading. Ser24 phosphorylation promotes membrane 
translocation of DAB2 and its interaction with beta3 
integrin. DAB2 negatively regulates integrin 
alphaIIbbeta3 activation, leading to the inhibition f 
alphaIIbbeta3-mediated fibrino-gen adhesion. In cell 
experiments during TGFbeta-induced epithelial to 
mesenchymal transdifferen-tiation (EMT), Dab2 
expression is increased and Dab2 binds to beta1  
integrin. In these conditions, Dab2 silencing leads to a 
decrease in cell adherence, inhibition of EMT, and 
apoptosis. 
Angiogenesis: DAB2 can bind to Shc3 domain of Src 
and this interaction results in Src inactivation. DAB2 is 
expressed in human umbilical vein endothelial cells 
(HUVEC). By modulating the activation of Src-FAK 
signaling and MAPK phosphorylation, DAB2 controls 
endothelial cell migration and differentiation. 
Homology 
The Disabled proteins are a family of adapters involved 
in cellular signaling, oncogenesis, and development. 
DAB2 is related to Drosophila Disabled and 
mammalian Dab1, which regulate neuronal 
development. DAB2 shares 81% identity with the 
mouse p96/Dab2 protein. 
Implicated in 
Epithelial ovarian cancer 
Note 
DAB2 was identified due to the loss of its expression in 
ovarian cancer cells. Ovarian carcinoma cells 
transfected with DAB2 showed a reduced growth rate 
and ability to form tumors in nude mice. Loss of DAB2 
expression is not correlated with tumor grade, 
suggesting that loss of DAB2 expression is an early 




DAB2 is a potent growth inhibitor for prostate cancer 
cells by suppressing several protein kinase pathways. 
The PRD of DAB2 is the key functional domain 
responsible for this activity. It was shown that in 
prostate cancer cells without endogenous DAB2 
expression, a functional motif derived from the PRD of 




DAB2 sensitizes breast cancer cells to cell death upon 
the loss of cell-matrix attachment by targeting the 
oncogenic activity of ILK. 
Various cancer 
Note 
Urothelial carcinoma of the bladder, esophageal 
squamous carcinoma, metastatic pancreatic cancer, 
colorectal cancer, gestational choriocarcinoma. 
Disease 
DAB2 expression is down-regulated. 
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Malignant peripheral nerve sheath 
tumor, invasive cervical carcinoma 
Note 
Comparative genomic hybridization (CGH) revealed 
frequent gains of DAB2. 
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